The information provided in this section is intended expressly for healthcare professionals in the United States. Click “OK” to enter if you are a US healthcare professional.
Recommended dosage in pediatric patients with body surface area of ≥1.0 m2: 100 mg taken orally twice daily until disease progression or until unacceptable toxicity
Recommended dosage in pediatric patients with body surface area <1.0 m2: 100 mg/m2 taken orally twice daily until disease progression or until unacceptable toxicity
Withhold VITRAKVI until adverse reaction resolves or improves to baseline or Grade 1. Resume at the next lower dose if resolution occurs within 4 weeks
Permanently discontinue VITRAKVI if an adverse reaction does not resolve within 4 weeks
Permanently discontinue VITRAKVI in patients who are unable to tolerate VITRAKVI after 3 dose modifications1
Dose modifications for coadministration with strong CYP3A4 inhibitors1
Avoid coadministration of strong CYP3A4 inhibitors with VITRAKVI. If coadministration of a strong CYP3A4 inhibitor cannot be avoided, reduce the VITRAKVI dose by 50%. After the inhibitor has been discontinued for 3 to 5 elimination half-lives, resume the VITRAKVI dose taken prior to initiating the CYP3A4 inhibitor
Dose modifications for coadministration with strong CYP3A4 inducers1
Avoid coadministration of strong CYP3A4 inducers with VITRAKVI. If coadministration of a strong CYP3A4 inducer cannot be avoided, double the VITRAKVI dose. After the inducer has been discontinued for 3 to 5 elimination half-lives, resume the VITRAKVI dose taken prior to initiating the CYP3A4 inducer
Dose modifications for patients with hepatic impairment1
Reduce the starting dose of VITRAKVI by 50% in patients with moderate (Child-Pugh B) to severe (Child-Pugh C) hepatic impairment